BRAF and neoplasm: By comparison, the use of very sensitive molecular techniques that would detect a minor BRAF-mutated subclone in a predominantly wild-type tumor may not be clinically relevant as BRAF inhibitors may have opposite signaling effects in cells with mutated or wild-type BRAF [49], [50].